Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of ACP-196 (acalabrutinib) in Waldenström Macroglobulinemia
2023-509356-34-00Phase 2Authorised
- Sponsor
- Acerta Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of acalabrutinib in Waldenström macroglobulinemia (WM) (2 cohorts), sponsored by Acerta Pharma. Primary endpoints: Overall response rate (WM criteria) and Overall response rate (modified 3rd IWWM criteria). Planned start Aug 2024; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2023-509356-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509356-34-00.